The National Pharmaceutical Pricing Authority Slashes the Prices for 35 crucial drugs
- The NPPA has reduced prices of 35 essential drugs, including anti-inflammatory, cardiovascular, antibiotic, anti-diabetic, and psychiatric medicines.
- Key affected drugs include Aceclofenac-Paracetamol combinations, Atorvastatin, Amoxycillin-Clavulanate, and newer anti-diabetics like Empagliflozin and Sitagliptin.
- Pediatric medicines like Cefixime-Paracetamol suspensions and Vitamin D drops are also covered.
- Retailers must display updated prices, with penalties for overcharging under DPCO 2013 and the Essential Commodities Act.
- The revised prices exclude GST, and manufacturers must update pricing through Form V submissions.
- The NPPA regulates drug pricing under the Ministry of Chemicals & Fertilisers to ensure affordability.
India's National Pharmaceutical Pricing Authority (NPPA) has implemented significant price cuts for 35 essential drugs spanning critical therapeutic areas to enhance medicine affordability. The sweeping reforms, approved by the Ministry of Chemicals and Fertilisers, target vital medications including pain relievers, heart disease treatments, antibiotics, diabetes drugs, and mental health prescriptions - offering substantial relief to chronic disease patients.
The comprehensive pricing overhaul affects some of India's most commonly prescribed medicines. Notable reductions include popular combinations like Aceclofenac-Paracetamol (now priced between Rs. 13-15.01 per tablet depending on manufacturer), life-saving cardiovascular drugs such as Atorvastatin-Clopidogrel (capped at Rs.25.61 per tablet), and advanced diabetes treatments combining Empagliflozin, Sitagliptin and Metformin. The policy extends its benefits to vulnerable populations through pediatric formulations like Cefixime-Paracetamol suspensions and essential injectables including Diclofenac (Rs. 31.77/ml).
Strict enforcement mechanisms accompany these revisions. All pharmacies must visibly display the updated pricing, with stringent penalties including financial repercussions for non-compliance under the Drugs (Prices Control) Order 2013. The new prices (GST-exclusive) require immediate implementation, with pharmaceutical firms mandated to update their systems through the Integrated Pharmaceutical Database Management System and submit revised Form V documentation to regulatory bodies.
Read More About Paracetamol Production Cost Reports - Request Free Sample Copy in PDF
This decisive action by India's premier drug pricing authority represents a significant stride in balancing healthcare accessibility with quality standards. By systematically overhauling pricing structures across both scheduled and non-scheduled medicines, the NPPA reinforces its commitment to affordable healthcare while maintaining rigorous pharmaceutical standards nationwide. The move is expected to particularly benefit long-term medication users and economically vulnerable patients across India's healthcare landscape.
The drugs that have been impacted by the latest price revisions are as follows:
- Aceclofenac + Paracetamol + Trypsin Chymotrypsin
- Amoxycillin + Potassium Clavulanate
- Atorvastatin + Clopidogrel
- Empagliflozin + Metformin
- Sitagliptin + Metformin
- Cefixime + Paracetamol (oral suspension)
- Cholecalciferol (Vitamin D) drops
- Diclofenac Injection
- Pantoprazole + Domperidone
- Rabeprazole + Domperidone
- Ambroxol + Guaiphenesin + Terbutaline
- Acebrophylline + Levocetirizine
- Bilastine + Montelukast
- Cefpodoxime + Clavulanic Acid
- Cefuroxime + Potassium Clavulanate
- Ofloxacin + Ornidazole
- Azithromycin + Ambroxol
- Moxifloxacin + Ketorolac
- Paracetamol + Phenylephrine + Caffeine
- Nimesulide + Paracetamol
- Aceclofenac + Paracetamol
- Glimepiride + Metformin + Pioglitazzne
- Metformin + Voglibose
- Linagliptin + Metformin
- Teneligliptin + Metformin
- Atorvastatin + Fenofibrate
- Rosuvastatin + Fenofibrate
- Telmisartan + Metoprolol
- Olmesartan + Amlodipine + Hydrochlorothiazide
- Escitalopram + Clonazepam
- Paroxetine + Clonazepam
- Clonazepam + Propranolol
- Amitriptyline + Chlordiazepoxide
- Fluoxetine + Olanzapine
- Risperidone + Trihexyphenidyl
